SCHEMBL3014668

SCHEMBL3014668

O=C1CCCN1S(=O)(=O)N1CCN(c2nc(-c3ccccc3)cs2)CC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.64
MAPK1 P28482 4/20 0.64
MEN1 O00255 3/20 0.64
KMT2A Q03164 3/20 0.64
SMN1; SMN2 Q16637 5/20 0.56
AR P10275 3/20 0.56
TP53 P04637 2/20 0.56
HSD17B10 Q99714 2/20 0.56
ALOX15 P16050 1/20 0.56
RAB9A P51151 7/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
NPC1 O15118 5/20 0.52
MAPT P10636 5/20 0.50
ALDH1A1 P00352 4/20 0.50
HTT P42858 2/20 0.50
NPSR1 Q6W5P4 1/20 0.49
CYP1A2 P05177 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
KDM4E B2RXH2 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3018443 0.85 LMNA (0.74) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL13208871 0.80 L3MBTL1 (0.66) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL18674596 0.78 MAPK1 (0.81) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL18674591 0.78 MAPK1 (1.00) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL18674670 0.78 AR (0.84) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3012515 0.76 LMNA (0.68) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL7092062 0.75 AR (0.70) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3019990 0.75 LMNA (0.67) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL18674671 0.75 AR (0.97) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL2998664 0.74 LMNA (0.68) LMNAMAPK1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP claimed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US claimed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US claimed
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA LMNA 80/4885MAPK1 2767/4885MEN1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.